Drugmakers Race to Market Lp(a) Treatments
Elevated levels of Lp(a), a common cardiovascular risk factor, currently lack effective drug therapies. Several pharmaceutical companies are advancing candidates toward market approval, aiming to address this unmet need.
Related stories
Pharma industry backs US inquiry into German reimbursement rules · Healthcare systems
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: New treatments for common cardiovascular risk factor near the market, with billions at stake.” Browse more stories.